SCHEMBL2184740

SCHEMBL2184740

CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCC(N)=O)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 12/20 0.66
NPY1R P25929 7/20 0.66
NPY2R P49146 5/20 0.66
FOLH1 Q04609 1/20 0.60
NPY5R Q15761 4/20 0.58
ACE P12821 1/20 0.53
IL1RN P18510 1/20 0.53
ERAP2 Q6P179 1/20 0.53
OPRM1 P35372 1/20 0.51
OPRD1 P41143 1/20 0.51
BACE1 P56817 1/20 0.51
BACE2 Q9Y5Z0 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184730 0.92 NPY4R (0.64) NPY4RNPY1RNPY2RFOLH1NPY5R
SCHEMBL29575832 0.91 NPY4R (0.60) NPY4RNPY1RNPY2RFOLH1NPY5R
SCHEMBL31257049 0.91 NPY4R (0.59) NPY4RNPY1RNPY2RNPY5ROPRM1
SCHEMBL30061881 0.89 NPY4R (0.63) NPY4RNPY1RNPY2RFOLH1NPY5R
SCHEMBL30317543 0.89 NPY4R (0.60) NPY4RNPY1RNPY2RFOLH1NPY5R
SCHEMBL29734944 0.89 FOLH1 (0.68) NPY4RNPY1RNPY2RFOLH1NPY5R
SCHEMBL29822390 0.89 FOLH1 (0.68) NPY4RNPY1RNPY2RFOLH1NPY5R
SCHEMBL5970156 0.89 NAALAD2 (0.56) NPY4RNPY1RNPY2RFOLH1ACE
SCHEMBL159465 0.89 NAALAD2 (0.56) NPY4RNPY1RNPY2RFOLH1ACE
SCHEMBL30198517 0.89 NPY4R (0.58) NPY4RNPY1RNPY2RFOLH1NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP NPY4R 567/4885NPY1R 544/4885NPY2R 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.